<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute palmoplantar eczema (dyshidrotic eczema)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute palmoplantar eczema (dyshidrotic eczema)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute palmoplantar eczema (dyshidrotic eczema)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Sasseville, MD, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Fowler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H26544681"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute palmoplantar eczema (more popularly known as dyshidrotic eczema or pompholyx) is an intensely pruritic, vesicular eruption affecting the palms, soles, or both [<a href="#rid1">1,2</a>]. It is characterized by deep-seated lesions ranging from small vesicles to large, tense bullae clinically and by spongiotic vesicles histologically. Recurrence is common, and patients typically experience frequent episodes for months or years.</p><p>This topic will discuss the pathogenesis, clinical presentation, diagnosis, and management of dyshidrotic eczema. Other forms of eczema involving the hands, including irritant and allergic contact dermatitis and atopic dermatitis, are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13661.html" rel="external">"Irritant contact dermatitis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13665.html" rel="external">"Management of allergic contact dermatitis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p></p><p class="headingAnchor" id="H26006232"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The terminology for acute palmoplantar eczema is confusing. The term "dyshidrosis" was coined in 1873 to describe a blistering disease of the palms and soles that was believed to be a disorder of the sweat glands [<a href="#rid3">3</a>]. It is now accepted that the sweat glands are not involved in the pathogenesis [<a href="#rid4">4,5</a>]. However, the term "dyshidrotic eczema" continues to be used.</p><p>Other terms for acute palmoplantar eczema include "pompholyx," "dyshidrosis," "vesicular palmoplantar eczema," "acute and recurrent vesicular hand dermatitis," "cheiropompholyx" (affecting the hands), or "podopompholyx" (affecting the feet). These terms do <strong>not</strong> represent a specific diagnosis but, rather, indicate a morphologic pattern of hand/foot eczema that can occur with irritant contact, allergic contact, or endogenous eczema.</p><p class="headingAnchor" id="H26544689"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Dyshidrotic eczema occurs most commonly in young adults and in females [<a href="#rid6">6</a>].</p><p>The prevalence of either mild or severe dyshidrotic eczema in the general population is unknown. A survey and examination of over 107,000 people in Sweden found a prevalence of 0.05 percent [<a href="#rid7">7</a>]. Among patients with hand dermatitis, dyshidrotic eczema accounts for 5 to 20 percent of cases [<a href="#rid3">3,8-10</a>].</p><p class="headingAnchor" id="H26544705"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The cause of dyshidrotic eczema is unknown, but it is probably multifactorial. Although, in most cases, a causative or predisposing factor cannot be identified, factors that have been associated with the development of dyshidrotic eczema include:</p><p class="bulletIndent1"><span class="glyph">●</span>History of atopic dermatitis [<a href="#rid11">11,12</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to contact allergens, particularly metals [<a href="#rid11">11,13,14</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to contact irritants (eg, metalworking fluids) [<a href="#rid15">15</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic exposure to contact allergens (eg, ingestion of nickel or cobalt) [<a href="#rid16">16</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dermatophyte infection at a distant site (id reaction) [<a href="#rid12">12</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with intravenous or subcutaneous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> [<a href="#rid13">13,17-22</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, an interleukin (IL) 17 inhibitor approved for the treatment of psoriasis and psoriatic arthritis [<a href="#rid23">23</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperhidrosis [<a href="#rid11">11</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Smoking [<a href="#rid24">24</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to ultraviolet (UV) radiation [<a href="#rid25">25</a>]</p><p></p><p class="headingAnchor" id="H2592800681"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The mechanisms underlying the development of dyshidrotic eczema are largely unknown. One hypothesis is that the overexpression of two water/glycerol channel proteins, aquaporin-3 and aquaporin-10, across all layers of the epidermis may alter the function of the epidermal water permeability barrier, with transepidermal water loss exacerbated by exposure to water and alkaline skin pH [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H26544713"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Episodes of dyshidrotic eczema often start with pruritus followed by a sudden, symmetric eruption of intensely pruritic vesicles on the palms, lateral and dorsal aspects of the fingers  (<a class="graphic graphic_picture graphicRef83010 graphicRef83056 graphicRef82783 graphicRef112980" href="/z/d/graphic/83010.html" rel="external">picture 1A-D</a>), or on the soles. In 70 to 80 percent of patients, only the hands are involved [<a href="#rid13">13</a>]. In mild cases, vesicles develop only on the lateral aspect of fingers  (<a class="graphic graphic_picture graphicRef112980 graphicRef83010" href="/z/d/graphic/112980.html" rel="external">picture 1A, 1D</a>). New episodes or worsening tend to be more common during the warmest months of the year.</p><p>The vesicles are typically deep seated and multilocular ("tapioca or sago pudding" lesions); they may coalesce into large bullae  (<a class="graphic graphic_picture graphicRef83007" href="/z/d/graphic/83007.html" rel="external">picture 2A</a>). In some patients, symptoms may be severe enough to interfere with occupational duties and daily activities  (<a class="graphic graphic_picture graphicRef83006" href="/z/d/graphic/83006.html" rel="external">picture 2B</a>).</p><p class="headingAnchor" id="H2925516636"><span class="h1">CLINICAL COURSE AND COMPLICATIONS</span><span class="headingEndMark"> — </span>Vesicles and bullae persist for several weeks, desiccate, and resolve with desquamation  (<a class="graphic graphic_picture graphicRef82782" href="/z/d/graphic/82782.html" rel="external">picture 3</a>) [<a href="#rid1">1,3</a>]. Frequent relapses may result in chronic hand dermatitis, characterized by red, lichenified, and scaling patches or plaques with fissures  (<a class="graphic graphic_picture graphicRef82784" href="/z/d/graphic/82784.html" rel="external">picture 1E</a>).</p><p>Episodes may recur at intervals of three to four weeks for months or years. In some patients, flares may be associated with emotional or physical stress, but most often, they occur in the absence of an identifiable trigger. Between episodes, the skin returns to a normal appearance, in contrast to the persistent signs and symptoms of chronic vesicular hand dermatitis secondary to irritant or allergic contact dermatitis or atopic dermatitis.</p><p>Severe episodes can affect the nail matrix and produce dystrophic nail changes such as horizontal ridging and color changes  (<a class="graphic graphic_picture graphicRef82784" href="/z/d/graphic/82784.html" rel="external">picture 1E</a>). Secondary infection, usually with <em>Staphylococcus aureus</em>, may occur.</p><p class="headingAnchor" id="H26544729"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H18792269"><span class="h2">Clinical diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of dyshidrotic dermatitis is usually made based upon clinical findings, symptoms, and history:</p><p class="bulletIndent1"><span class="glyph">●</span>Tense, deep-seated vesicles or bullae localized on the palms and soles and often on the lateral aspect of the fingers  (<a class="graphic graphic_picture graphicRef83056 graphicRef112980" href="/z/d/graphic/83056.html" rel="external">picture 1B, 1D</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tiny vesicles limited to the lateral aspect of fingers  (<a class="graphic graphic_picture graphicRef83010" href="/z/d/graphic/83010.html" rel="external">picture 1A</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intense pruritus</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute onset</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of recurrence</p><p></p><p class="headingAnchor" id="H95060809"><span class="h2">Assessment of severity</span><span class="headingEndMark"> — </span>The severity of dyshidrotic eczema is generally assessed subjectively. A scoring tool called the Dyshidrotic Eczema Area and Severity Index (DASI), based upon the number of vesicles, intensity of erythema, desquamation, and itch, was designed for use in clinical trials but is not routinely used in clinical practice [<a href="#rid28">28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild to moderate</strong> − We consider dyshidrotic eczema to be mild to moderate if it does not involve the entire palmar or plantar surface; presents as a few crops of vesicles or scattered, small vesicles with absent or modest erythema  (<a class="graphic graphic_picture graphicRef82784 graphicRef83056 graphicRef83053 graphicRef82781" href="/z/d/graphic/82784.html" rel="external">picture 1B, 1E-G</a>); and the patient does not complain of intolerable pruritus, burning, or pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe</strong> − We consider dyshidrotic eczema to be severe if it involves the entire palmar or plantar surface and presents with large vesicles or bullae that are disabling  (<a class="graphic graphic_picture graphicRef83007 graphicRef83006 graphicRef83055" href="/z/d/graphic/83007.html" rel="external">picture 2A-C</a>) (ie, prevent walking or use of the hands) or if it is intensely painful or pruritic (regardless of the size of the lesions).</p><p></p><p class="headingAnchor" id="H18792277"><span class="h2">Indications for biopsy</span><span class="headingEndMark"> — </span>A skin biopsy for histopathologic examination is rarely needed. Potential indications for skin biopsy include lack of response to treatment and exclusion of other conditions in the differential diagnosis (eg, psoriasis or palmoplantar pustulosis). </p><p>If a skin biopsy is performed, periodic acid-Schiff (PAS) staining for fungal elements may be useful in excluding a fungal infection. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H1806351875"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>The histologic features of dyshidrotic eczema depend upon the stage (acute or chronic) of the disease:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute stage</strong> − The acute form is characterized by intraepidermal spongiotic vesicles or bullae that do not involve the intraepidermal portion of the eccrine sweat duct (acrosyringium). A sparse, superficial, perivascular infiltrate of lymphocytes is usually present. The epidermal thickness is normal, and the thick stratum corneum of acral skin is intact. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic stage</strong> − In chronic cases, there is a predominance of parakeratosis and acanthosis with minimal or no spongiosis and a dermal, lymphocytic infiltrate.</p><p></p><p class="headingAnchor" id="H18792310"><span class="h2">Patch testing</span><span class="headingEndMark"> — </span>Patch testing is generally not helpful in making the diagnosis of dyshidrotic eczema. However, it is often performed by dermatologists to determine whether there is a component of allergic contact dermatitis. Patch testing may also be warranted in patients who do not respond to initial therapy [<a href="#rid1">1,3</a>]. (See  <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">"Patch testing"</a> and  <a class="medical medical_review" href="/z/d/html/13665.html" rel="external">"Management of allergic contact dermatitis in adults", section on 'Allergen avoidance'</a>.)</p><p class="headingAnchor" id="H26544737"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of dyshidrotic eczema includes inflammatory and infectious vesicobullous skin diseases [<a href="#rid1">1,3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic contact dermatitis</strong> – Allergic contact dermatitis may be clinically indistinguishable from dyshidrotic eczema  (<a class="graphic graphic_picture graphicRef82993 graphicRef83192" href="/z/d/graphic/82993.html" rel="external">picture 4A-B</a>). The correct diagnosis is based upon the assessment of allergen exposure and results of patch testing. (See  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bullous tinea</strong> – Bullous tinea occurs more often on the feet than on the hands and is usually unilateral  (<a class="graphic graphic_picture graphicRef54214 graphicRef82787" href="/z/d/graphic/54214.html" rel="external">picture 5A-B</a>). Potassium hydroxide (KOH) microscopic examination of scrapings from the lesions reveals fungal elements. (See  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections", section on 'Tinea pedis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritant contact dermatitis </strong>– Irritant contact dermatitis usually involves the dorsal aspect of the hands and web spaces  (<a class="graphic graphic_picture graphicRef50299 graphicRef59959" href="/z/d/graphic/50299.html" rel="external">picture 6A-B</a>). Patients often report a history of irritant exposure. Vesicles and bullae are rarely present, unless there was exposure to a strong irritant with a resultant chemical burn. (See  <a class="medical medical_review" href="/z/d/html/13661.html" rel="external">"Irritant contact dermatitis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopic hand dermatitis</strong> – Atopic hand dermatitis commonly involves the dorsum of the hands  (<a class="graphic graphic_picture graphicRef82881" href="/z/d/graphic/82881.html" rel="external">picture 7</a>). Patients report a history of atopic dermatitis, seasonal allergies, or asthma and may present with eczema lesions or lichenification involving flexural areas (ie, antecubital and popliteal fossae)  (<a class="graphic graphic_picture graphicRef82881" href="/z/d/graphic/82881.html" rel="external">picture 7</a>). (See  <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermatophytid (id) reaction</strong> – A dermatophytid reaction, also called "autoeczematization," is a secondary, pruritic, papulovesicular eruption that may occur on the palms in association with a dermatophyte infection at a distant site, more often on the foot but also on the scalp or other body area  (<a class="graphic graphic_picture graphicRef52664" href="/z/d/graphic/52664.html" rel="external">picture 8</a>). A complete skin examination and a KOH preparation of scrapings from suspicious lesions at a distant site are necessary to confirm the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections", section on 'Id reactions'</a> and  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpetic whitlow</strong> – Herpetic whitlow may mimic dyshidrotic eczema [<a href="#rid29">29</a>]. Typically, it presents as grouped vesicles on a red base, is more often painful than pruritic, and is usually unilateral  (<a class="graphic graphic_picture graphicRef52029" href="/z/d/graphic/52029.html" rel="external">picture 9</a>). The diagnosis can be made by viral culture, immunofluorescence staining, polymerase chain reaction, or Tzanck smear. (See  <a class="medical medical_review" href="/z/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palmoplantar pustulosis </strong>– Palmoplantar pustulosis may have an early, vesicular stage, but pustules usually develop in a few days  (<a class="graphic graphic_picture graphicRef62582 graphicRef82843" href="/z/d/graphic/62582.html" rel="external">picture 10A-B</a>). In 8 to 10 days, the pustules change their color to dark brown, become dry, and desquamate  (<a class="graphic graphic_picture graphicRef82842" href="/z/d/graphic/82842.html" rel="external">picture 11</a>). (See  <a class="medical medical_review" href="/z/d/html/89272.html" rel="external">"Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune bullous diseases</strong> – Bullous pemphigoid and pemphigus vulgaris may rarely present as localized disease involving the hands or feet  (<a class="graphic graphic_picture graphicRef50357" href="/z/d/graphic/50357.html" rel="external">picture 12</a>). The history reflects a longer and unremitting course. Biopsy for routine histology, direct immunofluorescence, and serologic testing for specific autoantibodies provide the correct diagnosis. (See  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus", section on 'Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H20269882"><span class="h1">CLINICAL COURSE</span><span class="headingEndMark"> — </span>Episodes of dyshidrotic eczema tend to spontaneously resolve over several weeks. However, dyshidrotic eczema is a recurrent disease, and patients typically experience frequent attacks of vesicular dermatitis for many years. Episodes tend to occur less frequently with age, and most patients eventually experience a complete remission [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H26544808"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Treatment is required for most patients who present with complaints of pruritus or other symptoms. The approach to management is guided by the severity of the disease (see <a class="local">'Assessment of severity'</a> above) and involves the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Identification and avoidance of causative or exacerbating factors</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of skin inflammation</p><p class="bulletIndent1"><span class="glyph">●</span>Adoption of skin care measures to reduce skin irritation</p><p></p><p class="headingAnchor" id="H16212203"><span class="h2">General measures</span><span class="headingEndMark"> — </span>In clinical experience, the avoidance of irritants or exacerbating factors is beneficial for most patients with dyshidrotic eczema. General skin care measures aimed at reducing skin irritation and restoring the skin barrier include [<a href="#rid31">31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Using lukewarm water and mild, synthetic detergent (nonsoap) cleansers to wash hands. Most liquid body cleansers are actually synthetic detergent products with a neutral pH. In contrast, "natural" soaps (eg, Castile soap) have an alkaline pH and tend to be more aggressive detergents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drying hands thoroughly after washing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Applying emollients (eg, petroleum jelly) immediately after hand drying and as often as possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wearing cotton gloves under vinyl or other nonlatex gloves when performing wet work.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Removing rings, watches, and bracelets before wet work.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wearing protective gloves in cold weather.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wearing task-specific gloves for frictional exposures (eg, gardening, carpentry).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding cutaneous exposure to irritants (eg, harsh detergents, solvents, hair dyes, acidic foods [eg, citrus fruit]).</p><p></p><p>In clinical practice, astringent solutions such as aluminum subacetate (Burow's solution) or <a class="drug drug_general" data-topicid="10319" href="/z/d/drug information/10319.html" rel="external">witch hazel</a> are used for wet, weeping skin. Hands or feet are soaked in the solution for 15 minutes two to four times per day. Alternately, soakings can be replaced by thin, wet dressings through which air will circulate, enhancing the drying effect of astringent solutions. Large bullae may be drained or aspirated using a sterile syringe to reduce pain and prevent spontaneous rupture with risk of local infection.</p><p class="headingAnchor" id="H16212111"><span class="h2">Mild to moderate disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical corticosteroids</strong> – For patients with mild to moderate dyshidrotic eczema  (<a class="graphic graphic_picture graphicRef82784 graphicRef83056 graphicRef83053 graphicRef82781" href="/z/d/graphic/82784.html" rel="external">picture 1B, 1E-G</a>) that has not responded to general measures, we suggest super high-potency or high-potency topical corticosteroids (groups 1 to 3  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>)) as first-line therapy. (See <a class="local">'Assessment of severity'</a> above and <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent1">Topical corticosteroids are applied twice daily for two to four weeks. Ointments are generally preferred to other vehicles (creams, solutions, or foams) because they contain fewer potential irritants and allergens, such as additives or preservatives [<a href="#rid1">1,3,31</a>]. However, some patients prefer other vehicles because ointments make their hands too greasy for performing tasks.</p><p></p><p class="bulletIndent1">The efficacy of topical corticosteroids versus placebo or no treatment for dyshidrotic eczema has not been adequately evaluated in randomized trials. However, they are used in clinical practice because of their anti-inflammatory properties and their efficacy in other forms of hand eczema. (See  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Topical corticosteroids'</a>.)</p><p></p><p class="bulletIndent1">The long-term use of topical corticosteroids is limited by their side effects, which include skin atrophy, striae, and telangiectasia. (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical calcineurin inhibitors</strong> – We generally do not suggest a topical calcineurin inhibitor as the first-line anti-inflammatory treatment for dyshidrotic eczema. The anti-inflammatory effect of topical calcineurin inhibitors is approximately equivalent to moderate-potency topical corticosteroids [<a href="#rid32">32</a>]. In addition, topical calcineurin inhibitors are more expensive than many topical corticosteroids.</p><p></p><p class="bulletIndent1">However, when patients and/or clinicians prefer to avoid long-term use of topical corticosteroids for the treatment of mild to moderate dyshidrotic eczema  (<a class="graphic graphic_picture graphicRef83053 graphicRef83056 graphicRef83010" href="/z/d/graphic/83053.html" rel="external">picture 1A-B, 1F</a>), the topical calcineurin inhibitor <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is an alternative [<a href="#rid33">33,34</a>]. Tacrolimus 0.1% ointment is applied twice daily until resolution.</p><p></p><p class="bulletIndent1">In a randomized trial including 16 patients with moderate to severe dyshidrotic eczema, topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> was compared with <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">mometasone</a> furoate, a high-potency topical corticosteroid (group 3) [<a href="#rid35">35</a>]. After four weeks of treatment ointment, both topical tacrolimus 0.1% and mometasone furoate 0.1% reduced the Dyshidrotic Eczema Area and Severity Index (DASI) by more than 50 percent compared with baseline.</p><p></p><p class="headingAnchor" id="H16212295"><span class="h2">Severe disease</span><span class="headingEndMark"> — </span>In addition to the general measures described above, we suggest a short course of oral corticosteroids for the treatment of severe dyshidrotic eczema  (<a class="graphic graphic_picture graphicRef83007 graphicRef83006 graphicRef83055" href="/z/d/graphic/83007.html" rel="external">picture 2A-C</a>). (See <a class="local">'Assessment of severity'</a> above and <a class="local">'General measures'</a> above.)</p><p>We generally start with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 60 mg once per day in the morning for one week. If there is an adequate response, the dose is then reduced by 50 percent in the next five to seven days and finally tapered and discontinued over the following two weeks.</p><p>Oral corticosteroids for dyshidrotic eczema have not been evaluated in clinical trials. However, in clinical experience, they have been beneficial for the short-term treatment of dyshidrotic eczema and other forms of severe, eczematous dermatitis. (See  <a class="medical medical_review" href="/z/d/html/1726.html" rel="external">"Management of severe atopic dermatitis (eczema) in children", section on 'Systemic corticosteroids'</a>.)</p><p>Superpotent topical corticosteroids applied under occlusive dressings (eg, polyethylene gloves for the hands or plastic wrap for the feet) are a treatment option for severe dyshidrotic eczema in patients for whom systemic glucocorticoids are contraindicated or in patients who prefer to avoid systemic corticosteroids. Occlusive dressings are usually used at nighttime for three to seven days.</p><p class="headingAnchor" id="H20269006"><span class="h2">Evaluation of treatment response</span><span class="headingEndMark"> — </span>Clinical criteria used to evaluate the response to treatment include cessation of vesiculation; clearance of pre-existing vesicles; and reduction of erythema, pruritus, and pain. Resolution is usually associated with increased skin dryness and desquamation. </p><p class="headingAnchor" id="H16212520"><span class="h2">Refractory disease</span><span class="headingEndMark"> — </span>Dyshidrotic eczema is considered refractory if there is no improvement/resolution in two to four weeks of adequate treatment. Refractory cases may warrant additional evaluation and reconsideration of the full differential diagnosis.</p><p class="headingAnchor" id="H16212528"><span class="h3">Additional diagnostic evaluation</span><span class="headingEndMark"> — </span>Patients with clinical features of dyshidrotic eczema who do not respond or are not adequately controlled after two to four weeks of topical corticosteroids, topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, or systemic corticosteroids may need further evaluation to confirm or rule out the diagnosis.</p><p>Additional testing may include (see <a class="local">'Differential diagnosis'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Potassium hydroxide (KOH) preparation to rule out a fungal infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial culture to rule out bacterial superinfection. Superinfection with <em>S. aureus</em> is a common cause of inadequate response to treatment in patients with hand eczema, especially with severe disease and wet, weeping lesions. Bacterial superinfection is treated with oral antibiotics. (See  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo", section on 'Systemic antibiotics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin biopsy and histopathologic examination to confirm the diagnosis of dyshidrotic eczema and exclude other conditions. Periodic acid-Schiff (PAS) staining for fungal elements should be included. Direct immunofluorescence may be necessary if bullous pemphigoid or pemphigus are suspected. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patch testing and detailed history of household- or work-related exposures to exclude an allergic or irritant contact dermatitis. (See  <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">"Patch testing"</a> and  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis", section on 'History'</a>.)</p><p></p><p class="headingAnchor" id="H16212550"><span class="h3">Treatment</span></p><p class="headingAnchor" id="H1012421193"><span class="h4">Phototherapy</span><span class="headingEndMark"> — </span>We suggest oral or topical psoralen plus ultraviolet A (PUVA) therapy or narrowband ultraviolet B (NBUVB) phototherapy for patients with a confirmed diagnosis of dyshidrotic eczema who have frequent or severe episodes that are not adequately controlled with topical or systemic corticosteroids or topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. (See  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a>.)</p><p>The use of NBUVB and PUVA for patients with dyshidrotic eczema is largely supported by its use in the treatment of other inflammatory dermatoses, as only a few small clinical trials have demonstrated clinical improvement with PUVA in patients with dyshidrotic eczema [<a href="#rid36">36-42</a>]. </p><p>Phototherapy may not be available in all communities. Phototherapy treatments are usually delivered two or three times per week. Several weeks of treatment are required to induce clinical improvement, and several months are required for resolution. Thus, the potential benefits of phototherapy should be weighed against the inconvenience of prolonged therapy on a case-by-case basis. Phototherapy that is limited to the palms and soles has few adverse effects. (See  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy", section on 'Topical PUVA'</a>.)</p><p class="headingAnchor" id="H1535616316"><span class="h4">Systemic therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic immunosuppressive agents</strong> – Systemic immunosuppressive agents, such as low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, have been occasionally used in the management of patients with severe dyshidrotic eczema [<a href="#rid43">43-45</a>]. However, their use has not been evaluated in high-quality studies, and there is insufficient evidence of benefit to suggest their use in refractory cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dupilumab</strong> – <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a>, an interleukin (IL) 4 receptor antagonist approved for the treatment of atopic dermatitis, has been shown to be well tolerated and effective in a small series of patients with dyshidrotic eczema who had previously failed topical corticosteroids [<a href="#rid45">45</a>]. A randomized, placebo-controlled trial evaluating the efficacy of dupilumab for hand eczema uncontrolled by superpotent topical corticosteroids is ongoing (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03861455&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPMlFadP8u8hbWwhU0Zjp%2F8GF9ibodsbIu4YRtvsByfRZA%3D%3D&amp;TOPIC_ID=13657" target="_blank">NCT03861455</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic retinoids</strong> – <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">Alitretinoin</a>, not available in the United States, is a systemic retinoid approved for the treatment of chronic, refractory hand eczema in the United Kingdom, Europe, and Canada. This oral retinoid exerts its anti-inflammatory and immunomodulatory effects through both the retinoid X receptor (RXR) and retinoic acid receptor (RAR). Initially expected to work better with hyperkeratotic hand eczema, it was found equally effective in vesicular hand dermatitis [<a href="#rid46">46,47</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">Alitretinoin</a> is usually given at the dose of 30 mg daily for six months. Upon stopping treatment, some patients experience prolonged remissions, while others will relapse more quickly. Treatment can be resumed when relapse occurs. Some patients may require continuous treatment.</p><p></p><p class="bulletIndent1">The most common adverse effect is headache during the first few weeks of treatment. Pregnancy precautions are similar to <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>. Where available, this medication has found a niche between superpotent topical corticosteroids or phototherapy and systemic immunosuppressive agents.</p><p></p><p class="headingAnchor" id="H26544941"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and risk factors</strong> – Acute palmoplantar eczema (also known as "dyshidrotic eczema" or "pompholyx") is a relatively uncommon, recurrent eruption affecting the palms, soles, or both. It occurs most commonly in young adults and more frequently in females. Main risk factors include a history of atopic dermatitis, exposure to contact irritants and allergens, and treatment with intravenous immunoglobulins. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Dyshidrotic eczema is characterized by the sudden eruption of intensely pruritic vesicles on the palms  (<a class="graphic graphic_picture graphicRef82781" href="/z/d/graphic/82781.html" rel="external">picture 1G</a>), soles, or lateral aspects of the fingers  (<a class="graphic graphic_picture graphicRef112980" href="/z/d/graphic/112980.html" rel="external">picture 1D</a>). The vesicles persist for several weeks, desiccate, and resolve with desquamation. Episodes may recur at intervals of three to four weeks for months or years. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of dyshidrotic eczema is usually based upon the clinical appearance and location of lesions, symptoms, and history. In selective patients with recalcitrant disease, patch testing is useful to determine whether there is a component of allergic contact dermatitis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of dyshidrotic eczema includes bullous tinea  (<a class="graphic graphic_picture graphicRef82787" href="/z/d/graphic/82787.html" rel="external">picture 5B</a>), dermatophytid reaction  (<a class="graphic graphic_picture graphicRef52664" href="/z/d/graphic/52664.html" rel="external">picture 8</a>), bullous impetigo, herpes simplex infection  (<a class="graphic graphic_picture graphicRef52029" href="/z/d/graphic/52029.html" rel="external">picture 9</a>), allergic contact dermatitis  (<a class="graphic graphic_picture graphicRef82993" href="/z/d/graphic/82993.html" rel="external">picture 4A</a>), and palmoplantar pustulosis  (<a class="graphic graphic_picture graphicRef62582 graphicRef82843" href="/z/d/graphic/62582.html" rel="external">picture 10A-B</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General measures</strong> – Avoidance of irritants or exacerbating factors is important for most patients with dyshidrotic eczema. (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate disease</strong> – For patients with mild to moderate dyshidrotic eczema  (<a class="graphic graphic_picture graphicRef82784 graphicRef83056 graphicRef83053 graphicRef82781" href="/z/d/graphic/82784.html" rel="external">picture 1B, 1E-G</a>) that has not responded to general measures (see <a class="local">'General measures'</a> above), we suggest super high-potency or high-potency topical corticosteroids (groups 1 to 3  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>)) as first-line therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Topical corticosteroids are applied twice daily for two to four weeks. Ointments are preferred to other vehicles. Topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is an alternative treatment for patients who wish to avoid long-term use of topical corticosteroids. (See <a class="local">'Mild to moderate disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe disease</strong> – In addition to the general measures described above, we suggest a short course of oral corticosteroids for the treatment of severe dyshidrotic eczema (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment is started with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 60 mg per day for one week. The dose may be reduced by 50 percent in the next five to seven days and then tapered and discontinued over the following two weeks. (See <a class="local">'Severe disease'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory disease</strong> – For patients with clinical features of dyshidrotic eczema whose disease does not respond or is not adequately controlled after two to four weeks of superpotent topical corticosteroids or systemic corticosteroids, further diagnostic evaluation may be needed to confirm or rule out the diagnosis. (See <a class="local">'Additional diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent2">For patients with confirmed, refractory dyshidrotic eczema, we suggest phototherapy with oral or topical psoralen plus ultraviolet A (PUVA) or narrowband ultraviolet B (NBUVB) therapy rather than systemic immunosuppressants (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Phototherapy'</a> above.)</p><p></p><p class="bulletIndent2">Oral <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a>, a systemic retinoid approved for the treatment of chronic, refractory hand eczema in the United Kingdom, Europe, and Canada (but not available in the United States), may be an alternative to phototherapy for patients with refractory dyshidrotic eczema. (See <a class="local">'Systemic therapies'</a> above.)</p><p></p><p class="headingAnchor" id="H359325921"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David R Adams, MD, PharmD, and James G Marks, Jr, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Veien NK. Acute and recurrent vesicular hand dermatitis. Dermatol Clin 2009; 27:337.</a></li><li><a class="nounderline abstract_t">Wollina U. Pompholyx: a review of clinical features, differential diagnosis, and management. Am J Clin Dermatol 2010; 11:305.</a></li><li><a class="nounderline abstract_t">Lofgren SM, Warshaw EM. Dyshidrosis: epidemiology, clinical characteristics, and therapy. Dermatitis 2006; 17:165.</a></li><li><a class="nounderline abstract_t">SHELLEY WB. Dysidrosis (pompholyx). AMA Arch Derm Syphilol 1953; 68:314.</a></li><li><a class="nounderline abstract_t">Kutzner H, Wurzel RM, Wolff HH. Are acrosyringia involved in the pathogenesis of "dyshidrosis"? Am J Dermatopathol 1986; 8:109.</a></li><li><a class="nounderline abstract_t">Gladys TE, Maczuga S, Flamm A. Characterizing demographics and cost of care for dyshidrotic eczema. Contact Dermatitis 2022; 86:107.</a></li><li><a class="nounderline abstract_t">Agrup G. Hand eczema and other hand dermatoses in south Sweden. Acta Derm Venereol (Stockh) 1969; 49 (Suppl 61):5.</a></li><li><a class="nounderline abstract_t">Meding B, Swanbeck G. Epidemiology of different types of hand eczema in an industrial city. Acta Derm Venereol 1989; 69:227.</a></li><li><a class="nounderline abstract_t">Agner T, Aalto-Korte K, Andersen KE, et al. Classification of hand eczema. J Eur Acad Dermatol Venereol 2015; 29:2417.</a></li><li><a class="nounderline abstract_t">Ortiz-Salvador JM, Esteve-Martínez A, García-Rabasco A, et al. Dermatitis of the Foot: Epidemiologic and Clinical Features in 389 Children. Pediatr Dermatol 2017; 34:535.</a></li><li><a class="nounderline abstract_t">Lodi A, Betti R, Chiarelli G, et al. Epidemiological, clinical and allergological observations on pompholyx. Contact Dermatitis 1992; 26:17.</a></li><li><a class="nounderline abstract_t">Pitché P, Boukari M, Tchangai-Walla K. [Factors associated with palmoplantar or plantar pompholyx: a case-control study]. Ann Dermatol Venereol 2006; 133:139.</a></li><li><a class="nounderline abstract_t">Guillet MH, Wierzbicka E, Guillet S, et al. A 3-year causative study of pompholyx in 120 patients. Arch Dermatol 2007; 143:1504.</a></li><li><a class="nounderline abstract_t">Jain VK, Aggarwal K, Passi S, Gupta S. Role of contact allergens in pompholyx. J Dermatol 2004; 31:188.</a></li><li><a class="nounderline abstract_t">de Boer EM, Bruynzeel DP, van Ketel WG. Dyshidrotic eczema as an occupational dermatitis in metal workers. Contact Dermatitis 1988; 19:184.</a></li><li><a class="nounderline abstract_t">Veien NK, Hattel T, Justesen O, Nørholm A. Oral challenge with metal salts. (I). Vesicular patch-test-negative hand eczema. Contact Dermatitis 1983; 9:402.</a></li><li><a class="nounderline abstract_t">Lehucher-Michel MP, Koeppel MC, Lanteaume A, Sayag J. Dyshidrotic eczema and occupation: a descriptive study. Contact Dermatitis 2000; 43:200.</a></li><li><a class="nounderline abstract_t">Uyttendaele H, Obadiah J, Grossman M. Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy. J Drugs Dermatol 2003; 2:337.</a></li><li><a class="nounderline abstract_t">Iannaccone S, Sferrazza B, Quattrini A, et al. Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease. Neurology 1999; 53:1154.</a></li><li><a class="nounderline abstract_t">Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. J Am Acad Dermatol 2012; 66:312.</a></li><li><a class="nounderline abstract_t">Shiraishi T, Yamamoto T. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome. Pediatr Dermatol 2013; 30:e30.</a></li><li><a class="nounderline abstract_t">Voland P, Barthel C, Azzouz B, et al. Intravenous and subcutaneous immunoglobulins-associated eczematous reactions occur with a broad range of immunoglobulin types: A French national multicenter study. J Am Acad Dermatol 2023; 88:380.</a></li><li><a class="nounderline abstract_t">Peera M, Smith A. Palmoplantar pompholyx secondary to interleukin 17A inhibitor therapy for psoriasis: A case series. JAAD Case Rep 2021; 13:46.</a></li><li><a class="nounderline abstract_t">Douwes KE, Karrer S, Abels C, et al. Does smoking influence the efficacy of bath-PUVA therapy in chronic palmoplantar eczema? Photodermatol Photoimmunol Photomed 2000; 16:25.</a></li><li><a class="nounderline abstract_t">Man I, Ibbotson SH, Ferguson J. Photoinduced pompholyx: a report of 5 cases. J Am Acad Dermatol 2004; 50:55.</a></li><li><a class="nounderline abstract_t">Bollag WB, Aitkens L, White J, Hyndman KA. Aquaporin-3 in the epidermis: more than skin deep. Am J Physiol Cell Physiol 2020; 318:C1144.</a></li><li><a class="nounderline abstract_t">Soler DC, Bai X, Ortega L, et al. The key role of aquaporin 3 and aquaporin 10 in the pathogenesis of pompholyx. Med Hypotheses 2015; 84:498.</a></li><li><a class="nounderline abstract_t">Vocks E, Plötz SG, Ring J. The Dyshidrotic Eczema Area and Severity Index - A score developed for the assessment of dyshidrotic eczema. Dermatology 1999; 198:265.</a></li><li><a class="nounderline abstract_t">Das S, Samudrala S, Chander R. Herpetic whitlow masquerading as pompholyx in a healthcare worker: revisiting the entity in today's era. Int J Dermatol 2021; 60:1168.</a></li><li><a class="nounderline abstract_t">Hald M, Agner T, Blands J, et al. Clinical severity and prognosis of hand eczema. Br J Dermatol 2009; 160:1229.</a></li><li><a class="nounderline abstract_t">Warshaw EM. Therapeutic options for chronic hand dermatitis. Dermatol Ther 2004; 17:240.</a></li><li><a class="nounderline abstract_t">Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005; 330:516.</a></li><li><a class="nounderline abstract_t">Belsito DV, Fowler JF Jr, Marks JG Jr, et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004; 73:31.</a></li><li><a class="nounderline abstract_t">Thelmo MC, Lang W, Brooke E, et al. An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema. J Dermatolog Treat 2003; 14:136.</a></li><li><a class="nounderline abstract_t">Schnopp C, Remling R, Möhrenschlager M, et al. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol 2002; 46:73.</a></li><li><a class="nounderline abstract_t">Tzaneva S, Kittler H, Thallinger C, et al. Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema. Photodermatol Photoimmunol Photomed 2009; 25:101.</a></li><li><a class="nounderline abstract_t">Polderman MC, Govaert JC, le Cessie S, Pavel S. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol 2003; 28:584.</a></li><li><a class="nounderline abstract_t">Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed 2007; 23:10.</a></li><li><a class="nounderline abstract_t">Petering H, Breuer C, Herbst R, et al. Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol 2004; 50:68.</a></li><li><a class="nounderline abstract_t">Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci 2018; 33:173.</a></li><li><a class="nounderline abstract_t">Väkevä L, Niemelä S, Lauha M, et al. Narrowband ultraviolet B phototherapy improves quality of life of psoriasis and atopic dermatitis patients up to 3 months: Results from an observational multicenter study. Photodermatol Photoimmunol Photomed 2019; 35:332.</a></li><li><a class="nounderline abstract_t">Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001; 26:343.</a></li><li><a class="nounderline abstract_t">Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol 1999; 40:612.</a></li><li><a class="nounderline abstract_t">Granlund H, Erkko P, Eriksson E, Reitamo S. Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol 1996; 76:371.</a></li><li><a class="nounderline abstract_t">Waldman RA, DeWane ME, Sloan B, et al. Dupilumab for the treatment of dyshidrotic eczema in 15 consecutive patients. J Am Acad Dermatol 2020; 82:1251.</a></li><li><a class="nounderline abstract_t">Diepgen TL, Pfarr E, Zimmermann T. Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol 2012; 92:251.</a></li><li><a class="nounderline abstract_t">Fowler JF, Graff O, Hamedani AG. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. J Drugs Dermatol 2014; 13:1198.</a></li></ol></div><div id="topicVersionRevision">Topic 13657 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19580928" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Acute and recurrent vesicular hand dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20642293" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pompholyx: a review of clinical features, differential diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17150166" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dyshidrosis: epidemiology, clinical characteristics, and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13079297" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Dysidrosis (pompholyx).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2940934" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Are acrosyringia involved in the pathogenesis of "dyshidrosis"?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34773262" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Characterizing demographics and cost of care for dyshidrotic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hand eczema and other hand dermatoses in south Sweden</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2566226" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epidemiology of different types of hand eczema in an industrial city.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371368" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Classification of hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28730653" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dermatitis of the Foot: Epidemiologic and Clinical Features in 389 Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1534730" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidemiological, clinical and allergological observations on pompholyx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508597" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : [Factors associated with palmoplantar or plantar pompholyx: a case-control study].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18086998" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A 3-year causative study of pompholyx in 120 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187338" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Role of contact allergens in pompholyx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2973394" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dyshidrotic eczema as an occupational dermatitis in metal workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6226480" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Oral challenge with metal salts. (I). Vesicular patch-test-negative hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11011918" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dyshidrotic eczema and occupation: a descriptive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12848120" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10496291" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21601310" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22304420" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36252685" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intravenous and subcutaneous immunoglobulins-associated eczematous reactions occur with a broad range of immunoglobulin types: A French national multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34141846" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Palmoplantar pompholyx secondary to interleukin 17A inhibitor therapy for psoriasis: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10721861" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Does smoking influence the efficacy of bath-PUVA therapy in chronic palmoplantar eczema?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14699365" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Photoinduced pompholyx: a report of 5 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32267715" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Aquaporin-3 in the epidermis: more than skin deep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25725905" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The key role of aquaporin 3 and aquaporin 10 in the pathogenesis of pompholyx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393450" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The Dyshidrotic Eczema Area and Severity Index - A score developed for the assessment of dyshidrotic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33650138" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Herpetic whitlow masquerading as pompholyx in a healthcare worker: revisiting the entity in today's era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19416249" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical severity and prognosis of hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15186370" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Therapeutic options for chronic hand dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15731121" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14964629" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522622" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756949" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19292787" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616819" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17254029" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14699368" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29067616" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A clinical review of phototherapy for psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31063610" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Narrowband ultraviolet B phototherapy improves quality of life of psoriasis and atopic dermatitis patients up to 3 months: Results from an observational multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422187" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Phototherapy for psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10188683" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8891011" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31926220" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Dupilumab for the treatment of dyshidrotic eczema in 15 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22281779" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25607554" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
